3 курс / Фармакология / Диссертация_Ромодановский_Д_П_Разработка_требований_для_оценки_фармакокинетики

417.Tothfalusi, L. Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk / L. Tothfalusi, L. Endrenyi // Stat Med. – 2017. – 36. – P. 4378–4390.

418.Tothfalusi, L. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence / Tothfalusi L., Endrenyi L. // AAPS J. – 2016. - 18(2). – P. 476-89.

419.Tothfalusi, L. Evaluation of bioequivalence for highly variable drugs with scaled average

bioequivalence / L. Tothfalusi, L. Endrenyi, A.A. García // Clin Pharmacokinet. – 2009. - 48(11).

– P. 725–43.

420.Tothfalusi, L. Sample Sizes for Designing Bioequivalence Studies for Highly Variable Drugs / L. Tothfalusi, L. Endrenyi // Journal of Pharmacy and Pharmaceutical Sciences. - 2012. - 15(1). - P. 73-84.

421.Tseng, C.M. Bioequivalence assessment of two simvastatin tablets in healthy Taiwanese volunteers. Journal of Food and Drug Analysis / C.M. Tseng, C.C. Huang, M.C. Ho [et a.] // Journal of Food and Drug Analysis. - 2007. - 15(1). - P. 15-19.

422.Van Gelder, T. What Is the Future of Generics in Transplantation? / T. van Gelder // Transplantation. – 2015. - 99(11). – P. 269-73.

423.Van Hecken, A. Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults / A. Van Hecken, B.B. Burckhardt, F. Khalil, [et al.] // Clin Pharmacol Drug Dev. – 2020. - 9(2). – P. 203-213.

424.Van Lancker, G. Switchability of Gabapentin Formulations: A Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level / G. Van Lancker, L. Van Bortel, B. Delafontaine [et al.] // Clin Pharmacol Ther. – 2019. - 106(1). - P. 195-203.

425.VanderLugt, J.T. Pharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects / J.T. VanderLugt, C. Bon, D. Knuth [et al.] // Clin Pharmacol Drug Dev. - 2018. - 7(3). - P. 311-318.

426.Vargas, M. Bioequivalence study of two formulations containing isotretinoin in fed condition in Colombian healthy volunteers / M. Vargas, E. Villarraga, P. Mantilla [et al.] // J Bioequiv Availab. - 2018. - 5(6). - P. 288‒291.

427.Vargas, M. Bioequivalence study of two formulations that contain isotretinoin 20 mg capsules in healthy Colombian volunteers / M. Vargas, E. Villarraga, M. Batista [et al.] // J Bioequiv Availab. - 2016. - 8(6). - P. 274-277.

428.Verbeeck, R.K. The lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions / R.K. Verbeeck, S. De Niet, S. Lebrun [et al.] // J Pharm Pharm Sci. - 2015. - 18(1). - P. 61-67.

381

429.Vespasiano, C.F. Bioequivalence study between a fixed-dose single-pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using highperformance liquid chromatography coupled to tandem mass spectrometry / C.F. Vespasiano, T.L. Laurito, R.D. Iwamoto [et al.] // Biomed Chromatogr. - 2017. - 31(5). - doi: 10.1002/bmc.3884.

430.Vijay, A. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics / A. Vijay, R. Gupta, P. Liu, [et al.] // J Gen Intern Med. – 2019. - doi: 10.1007/s11606-019-05432-6.

431.Vrbanac, H. The biorelevant simulation of gastric emptying and its impact on model drug dissolution and absorption kinetics / H. Vrbanac, J. Trontelj, S. Berglez, [et al.] // Eur J Pharm Biopharm. – 2020. -149. – P. 113-120.

432.Vree, T.B., Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose / T.B. Vree, E. Dammers, I. Ulc [et al.] // ScientificWorldJournal. - 2003. – 11(3). - P. 1332-1343.

433.Wagner, C.L. Bioequivalence Studies of Vitamin D Gummies and Tablets in Healthy Adults: Results of a Cross-Over Study / C.L. Wagner, J.R. Shary, P.J. Nietert [et al.] // Nutrients.

-2019. - 11(5). - P. 1023.

434.Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System [Электронный ресурс] // United States Food and Drug Administration. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070246.pdf (дата обращения: 11.05.2020).

435.Wang, C. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers / C. Wang, C. Hu, D. Gao [et al.] // Cancer Chemother Pharmacol. - 2019. - 83(3). - P. 509-517.

436.Wang, T. Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings / T. Wang, Y. Wang, S. Lin [et al.] // J Clin Lab Anal. – 2020. – doi:10.1002/jcla.23228.

437.Weidekamm, E. Lack of bioequivalence of a generic mefloquine tablet with the standard product / E. Weidekamm, G. Rusing, H. Caplain [et al.] // Eur J Clin Pharmacol. - 1998. - 54. - P. 615-619.

438.WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-Ninth

Report, 2015. [Электронный ресурс] // WHO World Health Organization. URL:

https://apps.who.int/iris/handle/10665/176954 (дата обращения: 11.05.2020).

382

439.Wonnemann, M. Inflation of the type I error: investigations on regulatory

recommendations for bioequivalence of highly variable drugs / M. Wonnemann, C. Frőmke, A.

Koch // Pharm Res. – 2015. – 32. – P. 135–143.

440.Wright, D.H. Bioequivalence of alendronate and vitamin d3 in a combination tablet versus corresponding-dose individual tablets in healthy Taiwanese volunteers, determined using a novel plasma alendronate assay / D.H. Wright, R. Mols, K.R. Brown [et al.] // Curr Ther Res Clin Exp. - 2015. - 77. - P. 116-121.

441.Wu, L. Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions / L. Wu, C. Xu, G. Wu [et al.] // Drug Des Devel Ther. - 2019. - 13(09). - P. 33313342.

442.Xie, F. In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example / F. Xie, S. Ji, Z. Cheng // Eur. J. Pharm. Sci. – 2015. – 66. – P. 163–172.

443.Xie, W. Quantitative liquid chromatographic and tandem mass spectrometric determination of vitamin D3 in human serum with derivatization: A comparison of in-tube LLE, 96-well plate LLE and in-tip SPME / W. Xie, C.M. Chavez-Eng, W. Fang [et al.] // Journal of Chromatography B. - 2011. - 879(17-18). - P. 1457-1466.

444.Xu, J. Optimal adaptive sequential designs for crossover bioequivalence studies / J. Xu, C. Audet, C.E. DiLiberti [et al.] // Pharmaceutical Stat. – 2016. – 15. – P. 15-27.

445.Xu, S.M. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of atorvastatin in Chinese subjects / S.M. Xu, J. Yan, D. Li [et al.] // Int J Clin Pharmacol Ther. – 2020. -58(2). – P. 112-120.

446.Yan, F. Design and inference for 3-stage bioequivalence testing with serial sampling data / F. Yan H., Zhu, J. Liu [et al.] // Pharmaceutical Stat. – 2018. – 17. – P. 458-76.

447.Yoon, D.Y. Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers / D.Y. Yoon, S.I. Park, J.A. Jung [et al.] // Drug Des Devel Ther. – 2020. -14. P. 661-668.

448.Yu, L.X. FDA Bioequivalence Standards. AAPS Advances in the Pharmaceutical Sciences / L.X. Yu, B.V. Li. - N.Y.: Springer, 2014. – 479 p.

449.Yu, Y. A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials / Y. Yu, S. Teerenstra, C. Neef [et al.] // Br J Clin Pharmacol. - 2016. - 81(4). - P. 667-78.

383

450.Yu, Y. Interchangeability of gabapentin generic formulations in the netherlands: a comparative bioavailability study / Y. Yu, S. Teerenstra, F. Vanmolkot [et al.] // Clinical Pharmacology & Therapeutics. - 2013. - 94(4). - P. 519-524.

451.Yu, Y.P. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data / Y.P. Yu, X.Y. Yan, C. Yao [et al.] // Biomed Environ Sci. – 2019. - 32(8). - P. 614-623.

452.Yun, M. Bioequivalence and pharmacokinetics of 70 mg alendronate sodium tablets by measuring alendronate in plasma / M. Yun, J. Woo, K. Kwon // Arch Pharm Res. - 2006. - 29(4).

-P. 328-332.

453.Zaid, A.N. Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers / A.N. Zaid, N. Kittana, A. Mousa [et al.] // Int J Clin Pharmacol Ther. - 2016. - 54(9). - P. 723-31.

454.Zaid, A.N. Biowaiver Eligibility of a Lower Strength Ramipril/Hydrochlorothiazide Immediate Release Tablets Using a New Validated HPLC Analytical Method / A.N. Zaid, M. Ghanem, L. Maqboul [et al.] // Drug Res (Stuttg). - 2016. - 66(10). - P. 539-546.

455.Zakeri-Milani, P. Pharmacokinetic study of two macrolide antibiotic oral suspensions using an optimized bioassay procedure / P. Zakeri-Milani, S. Ghanbarzadeh, F. Lotfi poor [et al.] // J Bioequiv Availab. - 2010. - 2. - P. 111-115.

456.Zhang, H. Pharmacokinetic drug interactions involving 17α-ethinylestradiol: a new look at an old drug / H. Zhang, D. Cui, B. Wang [et al.] // Clinical Pharmacokinetics. - 2007. - 46(2).

-P. 133-157.

457.Zhang, S. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of in vitro dissolution on in vivo absorption based on PBPK modeling / S. Zhang, M. Fang, Q. Zhang [et al.] // Drug Dev Ind Pharm. - 2019. - 45(10). - P. 1646-1653.

458.Zhang, X. Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence / X. Zhang, H. Wen, J. Fan [et al.] // CPT Pharmacometrics Syst Pharmacol. - 2017. - 6(8). - P. 523-531.

459.Zhang, X. Mechanistic oral absorption modeling and simulation for formulation development and bioequivalence evaluation: Report of an FDA public workshop / X. Zhang, J. Duan, F. Kesisoglou [et al.] // CPT Pharmacomet. Syst. Pharmacol. – 2017. - 6. – P. 92–495.

460.Zhang, Y. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax®

tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, referencereplicated crossover study / Y. Zhang, X. Chen, Y. Tang [et al.] // Drug Des Devel Ther. - 2017. - 11(07). - P. 2109-2119.

384

461.Zheng, J. On assessing bioequivalence and interchangeability between generics based on indirect comparisons / J. Zheng, SC. Chow, M. Yuan [et al.] // Stat Med. - 2017. - 36(19). - P. 2978-2993.

462.Zhu, H. A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH / H. Zhu, X. Chen, M. Ahmed [et al.] // Clin Transl Sci. - 2019. - 12(6). - P. 564-572.

463.Zhu, L. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter / L. Zhu, W. Sun // J Biopharm Stat. - 2019. - 29(5). - P. 776-799.

385

ПРИЛОЖЕНИЯ

Приложение 1 – Общие сведения по дизайну исследований биоэквивалентности воспроизведенных препаратов